Good PracticesIn Breast Cancer Care

Frederic Ivan Ting, MD Medical Oncologist



June 22, 2023



Disclosures


This event is sponsored by Novartis Healthcare Philippines, Inc.

Honoraria	Roche, Nestle, Pfizer, Good fellow, AMGEN	
Advisory Board Membership	Roche, AMGEN	
Clinical Trials	Pfizer, Astra Zeneca, Roche	



Cancer


Disease with uncontrolled growth of abnormal cells with the capacity to invade surrounding tissues and spread to distant sites





CANCER in the Philippines

Estimated number of incident cases and deaths World, Philippines, both sexes, all ages (excl. NMSC)





BREAST CANCER facts


3 out of a 100 Filipinos will develop cancer by 75 years old 1 out of 13 Filipino women will develop breast cancer in her lifetime



2015 Philippine cancer facts and estimates, http://thepafp.org/website/wp-content/uploads/2017/05/2015-PCS-Ca-Facts-Estimates CAN090516.pdf, Accessed October 2022. Image under license from: https://www.shutterstock.com/catalog/licenses?host=www.shutterstock.com/, accessed October 2022.



BREAST CANCER risk factors: Non-modifiable



Breast cancer risk factors, https://www.breastcancer.org/risk/risk-factors, accessed October 2022.



A Woman's Chances of Breast Cancer Increases With Age

By age 30 1 out of 227

By age 40 1 out of 68

By age 50 1 out of 42

By age 60 1 out of 28


By age 70 1 out of 26

By age 80 1 out of 8

2012 Cancer Stat Facts: Female Breast Cancer, accessed at: https://seer.cancer.gov/statfacts/html/breast.html, accessed on October 2022.



BREAST CANCER risk factors: Modifiable





BREAST CANCER risk factors

Having a risk factor or even several risk factors does <u>not</u> mean that you will surely get breast cancer.

Most women with breast cancer DO <u>NOT</u> have any known risk factors or even a history of the disease in their families.

BREAST CANCER signs/symptoms























BREAST CANCER screening

CORNERSTONES OF BREAST SCREENING

- Breast self awareness
- Clinical breast examination
- Mammography



Recommendations for BREAST CANCER screening




Mammogram yearly starting at age 40 – 45

55 – 74 years old: every 1-2 years


-American Cancer Society




Breast Self Examination (BSE)




Step 1:Examine Your Breasts in a Mirror With Hands on Hips




Step 2: Raise Arms and Examine Your Breasts



Step 3:Look for Signs of Breast Fluid



Step 4:Feel for Breast Lumps While Lying
Down



Step 5:Feel Your Breasts for Lumps
While Standing or Sitting




Inspect for:


Skin

- Dimpling
- Erythema
- Edema / thickening
- Scars

Nipple

- Crusting
- Dimpling
- Symmetry










Breast cancer screening: Why screen?

Ultimate goal = EARLY DETECTION






Triple test approach

- The most accurate approach to breast masses is a combination of:
 - Clinical breast exam (CBE)
 - Breast imaging studies
 - Needle biopsy

*If the triple test is concordant, there is a <1% risk of a missed malignancy



DIAGNOSIS: Core Needle Biopsy




The only sure way to determine whether a lump is cancer is to do a biopsy

Biopsy, https://www.breastcancer.org/screening-testing/breast-biopsy, accessed on October 2022.



MULTI-DISCIPLINARY TEAMS (MDTs)

are essential for optimal management of breast cancer patients



^{*} Patient requests, e.g. desire for neoadjuvant therapy, breast-conserving surgery vs. mastectomy. MDT, multidisciplinary team.

Chatterjee, Abhishek, and John K Erban. "Neoadjuvant therapy for treatment of breast cancer: the way forward, or simply a convenient option for patients?." *Gland surgery* vol. 6, : 119-124, 1 (2017). Cain, H., et al. "Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice." Clinical Oncology 29: 642-652., 10 (2017).





Breast cancer treatment





Our Mission

Clinician Lists

For Patients

Advancing a national dialogue around avoiding unnecessary medical tes

Our Mission

Our Mission

The mission of *Choosing Wisely* is to promote conversations between clinicians and patients by helping patients choose care that is:

- Supported by evidence
- Not duplicative of other tests or procedures already received
- Free from harm
- Truly necessary



Choosing Wisely Philippines: ten low-value or harmful practices that should be avoided in cancer care

Frederic Ivan Ting¹, Crizel Denise Uy², Katrina Gaelic Bebero³, Danielle Benedict Sacdalan⁴, Honey Sarita Abarquez⁵, Grace Nilo⁶, Buenaventura Ramos Jr⁷, Dennis L Sacdalan⁸ and Arnold John Uson⁹ on behalf of the Philippine Society of Medical Oncology (PSMO)

Abstract

The Choosing Wisely Philippines campaign is an initiative that identifies low-value or potentially harmful practices that are relevant to patients with cancer in the Philippines. The main purpose of these initiatives is to facilitate quality improvement systems and maximise patient outcomes. Of the ten practices identified, four are new recommendations, and six are modified adaptations from previous Choosing Wisely initiatives in the USA and Africa. Recommendations in the final list include interventions involving diagnosis (two practices), treatment (five practices), palliative and supportive care (two practices) and surveillance (1 practice).

Keywords: Choosing Wisely, Philippines, cancer care, practices



¹Riverside Bacolod Cancer Care Center, Bacolod 6100, Philippines

²San Juan De Dios Hospital, Manila 1000, Philippines

³Bishop Joseph Regan Memorial Hospital, Davao Del Norte 8100, Philippines

⁴University of Toronto, Toronto, ON M5G 1N6, Canada

⁵Davao Doctors Hospital, Davao City 8000, Philippines

⁶St. Luke's Medical Center - Global City, Manila 1000, Philippines

⁷Cebu Doctors University Hospital, Cebu City 6000, Philippines

⁸Philippine General Hospital, University of the Philippines, Manila 1000, Philippines

⁹Perpetual Succour Hospital, Cebu City 6000, Philippines













Table 1. CWP final list of low-value or harmful practices that should be avoided in cancer care.

	Origin of recommendation	Revisions made to original recommendation
Do not initiate cancer treatment without confirming the diagnosis, defining the extent of the cancer and discussing the intent of treatment with the patient.	Choosing Wisely Africa [4]	Yes
Do not use serum tumour markers indiscriminately for the screening and diagnosis of cancer.	New suggestion	Not applicable
Do not forget to discuss the value of biomarker testing for specific solid tumours where targeted treatments have proven benefits.	New suggestion	Not applicable
Do not decide treatment of potentially curable cancers without inputs from a multidisciplinary oncology team.	Choosing Wisely USA [1, 7]	No
Do not use surgery as the initial treatment without considering presurgical (neoadjuvant) systemic therapy and/or radiation for certain cancer types and stages where it is effective at improving local cancer control, quality of life or survival.	Choosing Wisely Africa [4]	No
Do not use combination cytotoxic chemotherapy when treating an individual for metastatic breast cancer unless the patient needs a rapid response to relieve tumour-related symptoms; instead, use a single cytotoxic agent.	Choosing Wisely USA [1]	Yes
Do not use cancer-directed therapy for patients with solid tumours with ALL of the following characteristics: low performance status (PS) (3 or 4), no benefit from prior evidence-based interventions and no strong evidence supporting the clinical value of further anti-cancer treatment. Instead, focus on symptom relief and palliative care.	Choosing Wisely USA and Africa [1, 4]	Yes
Do not use whole body Positron Emission Tomography - Computed Tomography (PET-CT) scans to detect recurrence after completing curative treatment for asymptomatic patients with early-stage solid tumours.	New suggestion	Not applicable
Avoid the use of granulocyte-colony stimulating factor (G-CSF) for primary prevention of febrile neutropenia for patients with less than 10%–20% risk for this complication.	Choosing Wisely USA [1]	Yes
Do not forget to discuss about alternative/herbal medications including its potential harmful consequences while on active cancer treatment.	New suggestion	Not applicable





Do not initiate cancer treatment without confirming the diagnosis, defining the extent of cancer and discussing the intent of treatment with the patient.

- Diagnosis
- Extent of cancer = Stage
- Treatment Goals



Do not forget to discuss the value of biomarker testing for specific solid tumors where targeted treatments have proven benefits.

- ER / PR / HER2 testing for Breast Cancer
- Check patient eligibility for targeted treatments



Do not decide treatment of potentially curable cancers without inputs from a multidisciplinary oncology team.

- MDT approach = Standard of care worldwide
- Best decisions on treatment approach = improved survival and better QoL

Source: Ting FI, Uy CD, Bebero KG, et al. Choosing Wisely Philippines: ten low-value or harmful practices that should be avoided in cancer care. *Ecancermedicalscience*. 2022;16:1424. Published 2022 Jul 7. doi:10.3332/ecancer.2022.1424



Do <u>not</u> use surgery as the initial treatment without considering presurgical (neoadjuvant) systemic therapy and/or radiation for certain cancer types and stages where it is effective at improving local cancer control, quality of life or survival.

- Presurgical treatment may:
 - Decrease the size of the primary tumour
 - improve resectability
 - reduces local recurrence
 - improve the patients' quality of life


Source: Ting FI, Uy CD, Bebero KG, et al. Choosing Wisely Philippines: ten low-value or harmful practices that should be avoided in cancer care. *Ecancermedicalscience*. 2022;16:1424. Published 2022 Jul 7. doi:10.3332/ecancer.2022.1424



Do not forget to discuss herbal medications including its potential harmful consequences while on active cancer treatment.

- There is no herbal supplement approved for the treatment of cancer by the Philippine FDA or international organizations
- Herbal medications also have inherent risks of toxicity
- Various drug interaction potential

False hope results in requests for healthcare interventions that deviate unreasonably from the standard of care




Deprivation of the chance to prepare for the end of life and die in dignity and comfort

Financial exploitation from unnecessary interventions

False hope in medically hopeless situations

Eijkholt M. Medicine's collision with false hope: The False Hope Harms (FHH) argument. Bioethics. 2020 Sep;34(7):703-11.

Important concerns for patients with cancer using CAM



Decreased effectiveness of conventional treatments

Treatment delay

Abandonment of conventional treatments

Reduced chance of cure or remission

Shorter survival time

Pirri C. Integrating complementary and conventional medicine. Cancer Forum. 2011;35(1):31-9.



*e*cancermedicalscience

The media and cancer: education or entertainment? An ethnographic study of European cancer journalists

Ajay Aggarwal^{1,2,3}, Rekha Batura^{1,3} and Richard Sullivan^{1,3}

¹Institute of Cancer Policy, Kings Health Partners Integrated Cancer Centre, Guy's NHS Foundation Trust Campus & Kings College London, Department of Research Oncology, Bermondsey Wing, London SE1 9RT, UK

²Guys & St Thomas' NHS Trust, Department of Clinical Oncology, London SE1 7EH, UK

³Kings College London, London SE1 9RT, UK

Correspondence to: Ajay Aggarwal. Email: ajay.aggarwal@kcl.ac.uk

Abstract

The media plays a vital role in informing the public about new developments in cancer research and influencing cancer policy. This is no easy task, in view of the myriad of trials and wonder drugs that purport to be the 'magic bullet'. However, misrepresentation can have profound consequences. In this qualitative study, we sought to understand the interaction between the media and cancer through the perspective of European science journalists by defining their attitudes towards current cancer research and challenges faced when reporting science news. A total of 67 respondents took part in this online survey, which was distributed by the European CanCer Organisation (ECCO) to all its media contacts between June and September 2013. Fifty-three per cent had over 20 years experience in reporting science news stories. The respondents utilised a number of media formats, including newsprint, online services, and radio.



The media and cancer: education or entertainment?

- The media plays a vital role in informing the public about new developments in cancer care and influencing cancer policy
- Coverage of cancer related issues and scientific advances require greater collaboration between the press and cancer healthcare community to provide both credibility and accountability for the health information disseminated

Source: Aggarwal A, Batura R, Sullivan R. The media and cancer: education or entertainment? An ethnographic study of European cancer journalists. *Ecancermedicalscience*. 2014;8:423. Published 2014 Apr 17. doi:10.3332/ecancer.2014.423



palliative care specialists family and caretakers ent – head and neck surgeons

surgical oncologists pathologists

care specialists medical oncologists nurses

Fighting cancer is a team effort.

radiologists radiation oncologists social worker

spiritual chaplains paramedical professionals

psychiatrists gynecologic oncologists

Media / Press

Let your faith be bigger than your fear.

Cancer is not a death sentence. There is always here

Email: f.ting@usls.edu.ph



Disclaimer

This is a non-promotional session and is supported by Novartis. The content is intended for medical educational purposes only. Novartis does not engage in the promotion of unregistered products or unapproved indications. Please consult local Prescribing Information for registration/product license details.



Novartis Healthcare Philippines, Inc. 5/F Ayala North Exchange Tower One Ayala Avenue corner Salcedo and Amorsolo Streets Brgy. San Lorenzo, Makati City 1223